Jocelyn Ulrich
Jocelyn Ulrich, MPH, is Vice President of Policy and Research at the Pharmaceutical Research and Manufacturers of America (PhRMA). At PhRMA, she is responsible for developing legislative and policy analysis and research studies on a range of issues impacting innovative biopharmaceutical companies including intellectual property issues, FDA policy issues, the R&D process, the value of innovation, and other issue areas impacting the environment for innovation. In addition to her experience at PhRMA she has over 15 years of experience in the pharmaceutical industry at Pfizer, Human Genome Sciences, and EMD Serono in roles in clinical research management, investigator-initiated and collaborative research, and global policy and corporate affairs. Jocelyn holds an MPH in global health policy and management from New York University.
Bayh-Dole: The fuel for America’s innovation engine
CMS proposal could discourage patient-centered innovation
ICYMI: Biopharmaceutical companies in America hit new investment milestone
16 years later: How BPCIA continues to expand competition and lower costs
Three things to know about 340B contract pharmacies
40 Years of Hatch-Waxman: How Can We Secure its Legacy?
40 Years of Hatch-Waxman: How does the Hatch-Waxman Act help patients?
Addressing the mounting threat of antimicrobial resistance
40 Years of Hatch-Waxman: What is the Hatch-Waxman Act?
Word of the Month: The Bayh-Dole Act
Word of the Month: AMR
Key considerations as Congress works towards PAHPA reauthorization
Policies need to address the growing threat of antimicrobial resistance
Protecting treatment advances for breast cancer
Don’t take anti-innovation, activist funded academics at their word
Biosimilar uptake is increasing and so are health savings
Research and development continues long after a medicine is initially approved
ICYMI: New report demonstrates growing global impact of antimicrobial resistance
Preventing the next public health emergency: New evidence demonstrates need to address antimicrobial resistance
ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response
The next threat: Combatting antimicrobial resistance
New Graphic: Public-Private collaboration fuels the U.S. biopharmaceutical ecosystem
R&D Focus: 5 things to know about the biopharmaceutical research ecosystem
Jocelyn Ulrich